bms 961 has been researched along with Acne in 1 studies
BMS 961: a retinoic acid receptor gamma agonist; no further info available 10/2006
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thoreau, E | 1 |
| Arlabosse, JM | 1 |
| Bouix-Peter, C | 1 |
| Chambon, S | 1 |
| Chantalat, L | 1 |
| Daver, S | 1 |
| Dumais, L | 1 |
| Duvert, G | 1 |
| Feret, A | 1 |
| Ouvry, G | 1 |
| Pascau, J | 1 |
| Raffin, C | 1 |
| Rodeville, N | 1 |
| Soulet, C | 1 |
| Tabet, S | 1 |
| Talano, S | 1 |
| Portal, T | 1 |
1 other study available for bms 961 and Acne
| Article | Year |
|---|---|
Structure-based design of Trifarotene (CD5789), a potent and selective RARĪ³ agonist for the treatment of acne.
Topics: Acne Vulgaris; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; | 2018 |